Three companies to expand market presence of new diabetes combo agent

Published: 2013-05-03 06:58:00

Updated: 2013-05-03 06:58:00

Three drug makers – Boehringer Ingelheim Korea, Lilly Korea and Yuhah Corp. – announced Tuesday that they will expand the market presence of Tranjenta Duo, a combination tablet of dipeptidyl peptidase-4 (DPP-4) inhibitor Trajenta (linagliptin) and metformin offering strong glycaemic control acros...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK